This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
13th May 2026

Company: Chordia Therapeutics Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: IR Manager Ami Kira
MAIL : info@chordiatherapeutics.com

Acceptance and Publication of Abstract on Dose-Escalation Cohort Data of rogocekib (CTX-712) at EHA 2026

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, "Chordia") announces that an abstract on its lead pipeline asset, the CLK inhibitor rogocekib (CTX-712), has been accepted for presentation and published online for the 2026 Annual Meeting of the European Hematology Association (EHA), to be held June 11–14, 2026, in Stockholm, Sweden.

The accepted presentation will include data from the dose-escalation cohorts of an ongoing Phase 1/2 clinical trial being conducted in the United States in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The presentation will report safety, pharmacokinetics, and preliminary efficacy data of rogocekib.

The EHA Annual Congress is one of the world's leading international congresses in the field of hematology. Chordia believes that the acceptance of this presentation reflects recognition by the global scientific community of the scientific rationale and clinical development progress of rogocekib. This presentation represents an important milestone in the development of rogocekib and provides a valuable opportunity to showcase Chordia's research and development capabilities on a global stage.

Further details of the presentation will be announced following the congress.

Chordia remains committed to steadily advancing the research and development of its pipeline, including rogocekib, with the goal of delivering new therapeutic options for patients with significant unmet medical needs.

Planned presentation overview of rogocekib, CLK inhibitor

Abstract No	EHA-3974
Title	SAFETY, TOLERABILITY, AND PRELIMINARY ACTIVITY OF ROGOCEKIB IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID MALIGNANCIES: RESULTS FROM A PHASE 1/2 STUDY (CTX-712-CL-02)
Session No	Poster
Time	June 13, 2026, 6:45 PM - 7:45 PM(CEST)
Abstract	SAFETY, TOLERABILITY, AND PRELIMINARY ACTIVITY OF ROGOCEKIB IN... - Garcia-Manero G - EHA-3974 - Jun 11 2026

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177) , CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website https://www.chordiatherapeutics.com/en/.